

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | 1 | — | — | — | 1 |
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | 1 | — | — | — | 1 |
| Infectious skin diseases | D012874 | — | — | — | 1 | — | — | — | 1 |
| Bacterial skin diseases | D017192 | — | — | — | 1 | — | — | — | 1 |
| Skin diseases | D012871 | — | L00-L99 | — | 1 | — | — | — | 1 |
| Streptococcal infections | D013290 | EFO_1001476 | — | — | 1 | — | — | — | 1 |
| Abscess | D000038 | EFO_0003030 | — | — | 1 | — | — | — | 1 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 1 | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | — | — | — | 1 |
| Drug common name | RADEZOLID |
| INN | radezolid |
| Description | Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Melinta Therapeutics, Inc. for the treatment of bacterial acne.
|
| Classification | Small molecule |
| Drug class | oxazolidinone antibacterials |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(CNCc4cnn[nH]4)cc3)c(F)c2)C(=O)O1 |
| PDB | — |
| CAS-ID | 869884-78-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL455461 |
| ChEBI ID | — |
| PubChem CID | 11224409 |
| DrugBank | — |
| UNII ID | 53PC6LO35W (ChemIDplus, GSRS) |
